PHIOGEN Information

PHIOGEN is developing first-in-class immunizing therapeutics that leverage immunomodulation to eliminate bacterial infections and generate durable immune protection against future recurrence. By transforming treatment into long-term prevention, we aim to replace repeated infections and chronic antibiotic use with lasting, potentially one-time solutions for patients facing recurrent and drug-resistant bacterial diseases. A spin-out from Baylor College of Medicine, PHIOGEN operates from its dedicated lab at Helix Park within the Texas Medical Center, the world’s largest medical complex. The company’s proprietary platform integrates advanced screening, human-relevant models, and evolutionary selection to develop dual-action biotherapeutics that both eliminate bacterial pathogens and stimulate protective immunity. To learn more please visit www.phiogen-pharma.com